SCHEMBL24674313

SCHEMBL24674313

Fc1ccc(-c2cnc3ncnc(Cl)c3c2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 2/20 0.44
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 1/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
LMNA P02545 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
DYRK1A Q13627 3/20 0.38
CLK2 P49760 2/20 0.38
CLK1 P49759 2/20 0.38
DYRK1B Q9Y463 2/20 0.38
EGLN1 Q9GZT9 1/20 0.38
DYRK2 Q92630 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
HPGD P15428 1/20 0.37
CYP2C19 P33261 1/20 0.37
PDGFRB P09619 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29427690 1.00 MAP4K4 (0.44) MAP4K4ALDH1A1KDM4EMAPTMAPK1
SCHEMBL22726035 0.81 MAP4K4 (0.43) MAP4K4KDM4ELMNACLK4CYP1A2
SCHEMBL3338539 0.77 MAP4K4 (0.66) MAP4K4ALDH1A1MAPK1LMNACLK4
SCHEMBL22726057 0.74 CD38 (0.46) MAP4K4KDM4ELMNACLK4EGFR
SCHEMBL1113980 0.73 MAP4K4 (0.53) MAP4K4ALDH1A1KDM4EMAPTMAPK1
SCHEMBL4419997 0.71 MAP4K4 (0.39) MAP4K4ALDH1A1KDM4EMAPTMAPK1
SCHEMBL22726055 0.70 PARP1 (0.55) KIT
SCHEMBL22714176 0.70 NOS1 (0.48) ALDH1A1KDM4EMAPK1LMNASMN1; SMN2
SCHEMBL29427694 0.70 PARP1 (0.55) KIT
SCHEMBL29427710 0.70 NOS1 (0.48) ALDH1A1KDM4EMAPK1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606562-B2 Pyridopyrimidines derivatives as P2X3 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2026-04-21 US disclosed
US-20230212169-A9 PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2023-07-06 US disclosed
US-20230212169-A9 PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2023-07-06 US disclosed
US-20230212169-A9 PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2023-07-06 US disclosed
US-20220235060-A1 PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS CHIESI FARM SPA (IT) 2022-07-28 US disclosed
US-20220235060-A1 PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS CHIESI FARM SPA (IT) 2022-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220235060-A1 PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS P2RX3, P2RX5, P2RX1 MAP4K4 2070/4885ALDH1A1 1027/4885KDM4E 3807/4885
US-12606562-B2 Pyridopyrimidines derivatives as P2X3 inhibitors P2RX3, P2RX1, P2RX2 MAP4K4 3995/4885ALDH1A1 999/4885KDM4E 4535/4885
US-20230212169-A9 PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS P2RX3, P2RX5, P2RX1 MAP4K4 2070/4885ALDH1A1 1027/4885KDM4E 3807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.